Version 1
: Received: 5 September 2024 / Approved: 6 September 2024 / Online: 6 September 2024 (16:48:36 CEST)
How to cite:
Aboubechara, J. P.; Aboud, O. Metabolic Risk Factors and Survival in Patients with Glioblastoma. Preprints2024, 2024090546. https://doi.org/10.20944/preprints202409.0546.v1
Aboubechara, J. P.; Aboud, O. Metabolic Risk Factors and Survival in Patients with Glioblastoma. Preprints 2024, 2024090546. https://doi.org/10.20944/preprints202409.0546.v1
Aboubechara, J. P.; Aboud, O. Metabolic Risk Factors and Survival in Patients with Glioblastoma. Preprints2024, 2024090546. https://doi.org/10.20944/preprints202409.0546.v1
APA Style
Aboubechara, J. P., & Aboud, O. (2024). Metabolic Risk Factors and Survival in Patients with Glioblastoma. Preprints. https://doi.org/10.20944/preprints202409.0546.v1
Chicago/Turabian Style
Aboubechara, J. P. and Orwa Aboud. 2024 "Metabolic Risk Factors and Survival in Patients with Glioblastoma" Preprints. https://doi.org/10.20944/preprints202409.0546.v1
Abstract
Background
The metabolic syndrome increases the risk of developing various systemic cancers. The prevalence of the metabolic syndrome in newly diagnosed glioblastoma patients is unknown. Further, there have been contradictory reports about how the metabolic syndrome affects clinical outcomes. Therefore, the purpose of this study is to test the hypothesis that the metabolic syndrome is associ-ated with increased prevalence of glioblastoma and worsened survival outcomes.
Methods
This retrospective cohort study examines seventy-three patients with isocitrate dehydrogenase (IDH)-wild type glioblastoma as it provides for a relatively homogeneous population to examine. Patient characteristics, vital signs, lab results, tumor molecular markers, and overall survival were analyzed. Patients with the metabolic syndrome and individual risk factors were identified and survival outcomes were examined.
Results
Our results demonstrate that there is a higher prevalence of the metabolic syndrome in our cohort of patients with glioblastoma than the general population (41% vs 33%). We also demonstrate that after correction for confounding variables, the metabolic syndrome is not significantly asso-ciated with overall survival (p = 0.1). When analyzing individual metabolic risk factors, we demonstrate that there is a significant association between the accumulation of metabolic risk factors and decreased survival (p = 0.03), and hyperglycemia emerges as a significant independent risk factor for decreased survival (p = 0.05).
Conclusion
These results suggest that metabolic risk factors can affect survival in patients with glioblastoma, which can have significant implications for clinical practice. These findings need to be further ex-plored through further clinical and mechanistic studies.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
